



## **Sickle Cell Disease and COVID-19: An Outline to Decrease Burden and Minimize Morbidity**

**Medical and Research Advisory Committee  
Sickle Cell Disease Association of America**

***This document will be updated once weekly on Friday afternoons as data and evidence emerge.***

As of March 17, 2020, there are 188,421 infected and 7,499 deaths from COVID-19 worldwide. While most of these patients are in the Hubei province of China, the numbers in the United States are climbing exponentially with 4,748 cases and 93 deaths. The major morbidity and mortality from COVID-19 is described by Guan et al. NEJM 2020. In a cohort of 1099 patients, the median age of the patients was 47 years; 41.9% of the patients were female. Of this cohort, 5.0% were admitted to the ICU, 2.3% underwent invasive mechanical ventilation, and 1.4% died. The most common symptoms were fever (43.8% on admission and 88.7% during hospitalization) and cough (67.8%). On admission, ground-glass opacity was the most common radiologic finding on chest computed tomography (CT) (56.4%). No radiographic or CT abnormality was found in 157 of 877 patients (17.9%) with non-severe disease and in 5 of 173 patients (2.9%) with severe disease. It is clear from the work of our colleagues in China and Italy, that the disease is particularly devastating to individuals with pre-existing conditions.

Sickle cell disease (SCD) affects 100,000 individuals in the United States and many more world-wide. A major cause of morbidity and mortality in these individuals is acute chest syndrome (ACS) which is the term used for a constellation of findings that includes chest pain, cough, fever,

hypoxia (low oxygen level) and lung infiltrates. Acute chest syndrome may be the result of sickling in the small blood vessels, pulmonary infarction/emboli or viral or bacterial pneumonia. The management of ACS is challenging and requires vigilance from the medical team. There is a significant concern that the overlap of lung disease from COVID-19, in the setting of sickle cell lungs already primed for and scarred from acute chest syndrome may result in significant complications and amplification of healthcare utilization. Moreover, individuals with sickle cell disease have high utilization of acute care services including emergency departments and hospitals and often present with fever, signs and symptoms of pneumonia or evolving ACS, as well as acute sickle cell pain requiring parenteral therapy. Thus, there may be specific diagnostic, treatment and logistical challenges in meeting the healthcare needs of this population in the midst of the COVID-19 pandemic.

Here, we provide guidelines for providers who may encounter patients suspected of being infected with COVID-19 and having sickle cell disease.

Specifically, for sickle cell disease patients:

#### • **Clinic Flow and Strategies to Meet Transfusion Demands**

- Over the next several weeks, we will be inundated with persons under investigation (PUI) for COVID-19. Make every effort to interview the “person of interest” by telephone, text monitoring system, or video conference. Temperature monitoring could be reported by phone or shown to a provider via video conferencing.
- If possible, reschedule all routine appointments for the next 4-6 weeks. Push your institution to have virtual appointments and electronic refills.
- Reach out to your state board to have a waiver on duration of opioid prescriptions. (for example, the New York State Board has given three-month waivers to sickle cell patients).

- Halt all new research enrollment, including gene therapy/bone marrow transplantation
- Use enhanced discretion when ordering transfusions in sickle and non-sickle cell patients in the hospital and require all transfusions to be approved by hematology.
- Medical leaders should encourage local communities and political leadership to support local blood drives as blood shortages are anticipated.
- In the setting of blood shortage, clinicians will need to prioritize transfusion according to clinical need. Highest priorities include patients with recent stroke, progressive or critical neurovascular disease and those with repeated acute chest syndrome despite Hydroxyurea and significant cardiac or respiratory co-morbidity. Consider transitioning to Hydroxyurea for patients eligible according to TWITCH criteria. (Ware et al Lancet 2016)
- For patients with fever and cough
  - If possible at your center – test ALL patients for COVID-19.
  - Follow standard operating procedures for sickle cell disease and fever.
  - Consider minimizing hospitalizations if COVID-19 negative and manageable with outpatient antibiotics.

### **COVID-19+ Treatment in Patients with Sickle Cell Disease**

- Consider early aggressive simple or exchange transfusion for patients with SCD and COVID-19 with fever and cough. This should certainly be done in patients with worsening anemia, evidence of hypoxia and chest x-ray changes, but may be done in the absence of these indications. This recommendation is based on H1N1 and sickle cell disease experience (Inusa et al Blood 2011, Jacobs et al PBC 2011).

- General respiratory measures for infected patients are to avoid aerosol-based interventions.
  - Nebulizers should not be used in a non-negative pressure room, instead use metered-dose inhaler for Albuterol
  - No non-invasive ventilation or high flow oxygen, or bronchoscopy on the general floors; should only be done in negative pressure rooms
  - Non-invasive oxygen therapy should progress to intubation to limit aerosolization and infection risk.
- Prophylactic antibiotic management and use oseltamivir until influenza ruled out
- Steroids are contraindicated until we have more data on immune system responses.
- Patients should be assessed for pulmonary hypertension and right ventricle dysfunction. Providers may consider inhaled nitric oxide in the setting of these entities.
- For severe and progressive cases, consider prone ventilation, inhaled nitric oxide (preferred) or Epoprostenol therapy, paralysis, and extra-corporeal membrane oxygenation.
- At the discretion of providers, Ritonavir/Lopinovir, Tocilizumab or Hydroxychloroquine may be used.
- The data around non-steroidal anti-inflammatory drugs, angiotensin converting enzyme inhibitors and angiotensin II receptor blockers are not clear and decisions about these drugs should be made on a case-by-case basis.

The coming months will be unprecedented in the history of healthcare. These recommendations serve as a template that may be beneficial when navigating this uncharted territory.

Authors listed below. In **Bold** are the authors responsible for the weekly updates. Their e-mails are available for suggestions/questions/comments.

## SCDAA Medical and Research Advisory Committee Members

### **Miguel R Abboud, MD**

Professor of Pediatrics and Pediatric  
Hematology-Oncology  
Chairman  
Department of Pediatrics and Adolescent  
Medicine  
American University of Beirut, Lebanon

### **Biree Andemariam, MD**

**Chair, Medical and Research Advisory  
Committee, Sickle Cell Disease Association  
of America  
Chief Medical Officer, Sickle Cell Disease  
Association of America  
Director, New England Sickle Cell Institute  
Associate Professor of Medicine  
University of Connecticut Health  
Farmington, CT 06030  
andemariam@uchc.edu**

### **Shawn Bediako, PhD**

Associate Professor  
Department of Psychology  
University of Maryland Baltimore County  
Baltimore, Maryland

### **Andrew Campbell, MD**

Center for Cancer and Blood Disorders  
Children's National Health System  
Associate Professor of Pediatrics  
George Washington University School of  
Medicine and Health Sciences

### **Raffaella Colombatti, MD, PhD**

**Physician Azienda Ospedaliera-Università  
di Padova  
Department of Womens' and Child Health  
Clinic of Pediatric Hematology Oncology  
Via Giustiniani 3  
35129 Padova Italy  
raffaella.colombatti@aopd.veneto.it**

### **Lori Crosby, PsyD**

Co-Director, Innovations in Community  
Research, Division of Behavioral Medicine &  
Clinical Psychology  
Co-Director, CCTST, Community  
Engagement Core  
Psychologist, Research, Behavioral Medicine  
& Clinical Psychologist  
Cincinnati Children's  
Professor, UC Department of Pediatrics

### **Deepika Darbari, MD**

Center for Cancer and Blood Disorders  
Children's National Health System  
Associate Professor of Pediatrics  
George Washington University School of  
Medicine and Health Sciences

### **Payal Desai, MD**

Associate Professor  
Director of Sickle Cell Research  
The Ohio State University  
JamesCare at Ohio State East Hospital  
181 Taylor Avenue  
Columbus, Ohio 43203

**James Eckman, MD**

Professor Emeritus, Hematology & Medical  
Oncology  
Emory University School of Medicine  
Department of Hematology and Medical  
Oncology  
49 Jesse Hill Jr. Drive SE  
Atlanta, GA 30303

**Mark Gladwin, MD**

Professor and Chair  
Department of Medicine  
Founder, Pittsburgh Heart, Lung, and Blood  
Vascular Medicine Institute  
University of Pittsburgh  
E1240 BST  
200 Lothrop Street  
Pittsburgh, PA 15261

**Jo Howard, MB Bchir, MRCP, FRCPath**

Head of Red Cell/Sickle Cell Service  
Guy's and St Thomas'  
NHS Foundation Trust  
Great Maze Pond  
London, United Kingdom

**Lewis Hsu, MD, PhD**

**Co-Chair, Medical and Research Advisory  
Committee, Sickle Cell Disease Association  
of America**  
**Vice Chief Medical Officer, Sickle Cell  
Disease Association of America**  
**Director of Pediatric Sickle Cell**  
**Professor of Pediatric Hematology-  
Oncology**  
**University of Illinois at Chicago**  
**Chicago, Illinois**  
**lewhsu@uic.edu**

**Baba Inusa, MRCP, FRCPCH, DCP (Haem)**

Honorary Reader in Paediatric  
Haematology, King's College London  
Lead Consultant Sickle Cell and  
Thalassaemia Service  
Evelina London Children's Hospital  
St Thomas' Hospital  
Westminster Bridge Road  
London, United Kingdom

**Elizabeth S. Klings, MD**

Associate Professor of Medicine  
Director, Center for Excellence in Sickle Cell  
Disease  
Director, Pulmonary Hypertension Center  
Boston University School of Medicine  
72 East Concord Street, R-304  
Boston, MA 02118

**Lakshmanan Krishnamurti, MD**

Professor of Pediatrics, Director of BMT  
Joseph Kuechenmeister Aflac Field Force  
Chair  
Aflac Cancer and Blood Disorders Center  
Children's Healthcare of Atlanta/Emory  
University

**Sophie Lanzkron, MD, MHS**

Director, Sickle Cell Center for Adults  
The Johns Hopkins Hospital  
1800 Orleans St  
Baltimore, MD 21287

**Caterina Minniti, MD**

Director, Sickle Cell Center  
Montefiore Health System  
Professor of Medicine and Pediatrics  
Albert Einstein College of Medicine  
cminniti@montefiore.org

**Genice T. Nelson, DNP, APRN, ANP-BC**

Program Director  
New England Sickle Cell Institute &  
Connecticut Bleeding Disorders Programs  
UConn Health  
Farmington, CT 06030  
Board Member, Sickle Cell Disease  
Association of America

**Isaac Odame, MB ChB, MRCP(UK), FRCPath,  
FRCPC, FRCPC**

Professor, Department of Paediatrics  
University of Toronto  
The Hospital for Sick Children  
Division of Haematology/Oncology  
555 University Avenue  
Toronto, Ontario M5G 1X8

**Gwendolyn Poles, D.O.**

Honorary Medical Staff Member  
Former Medical Director, Kline Health  
Center  
Faculty, Internal Medicine Program  
UPMC Pinnacle  
Harrisburg, PA  
Board Member, Sickle Cell Disease  
Association of America

**John Roberts, MD**

Yale Adult Sickle Cell Program  
Smilow Cancer Hospital at Yale New Haven  
35 Park Street, Ste 7th floor, Multispecialty  
New Haven, CT 06511

**Wally Smith, MD**

Professor  
Scientific Director, VCU Center on Health  
Disparities  
Director, VCU Adult Sickle Cell Program  
Department of Internal Medicine  
Division of General Internal Medicine  
West Hospital W10W-403  
P.O. Box 980306  
Richmond, VA 23298

**Crawford J Strunk MD**

Pediatric Hematology/Oncology  
Pediatric Hematology/Oncology Program at  
Toledo Children's Hospital  
2142 N. Cove Blvd.  
Toledo, Ohio 43606

**Immacolata Tartaglione, MD PhD**

Department of Woman, Child and General  
and Specialist Surgery  
Università degli Studi della Campania "Luigi  
Vanvitelli"  
Naples, Italy

**Marsha Treadwell, PhD**

Director, Northern California, Network of  
Care for Sickle Cell Disease  
Co-Principal Investigator and Regional  
Director, Pacific Sickle Cell Regional  
Collaborative  
Director, Hematology Behavioral Services  
Comprehensive Center for Sickle Cell  
Disease, Main Hospital  
747 52nd Street  
Oakland, CA 94609

**Winfred C. Wang, MD**

Member, Department of Hematology  
St. Jude Children's Research Hospital  
262 Danny Thomas Place, MS 800  
Memphis, TN 38105

**Russell E. Ware, MD, PhD**

Director, Division of Hematology  
Institute Co-Director, Cancer and Blood  
Diseases Institute  
Director, Global Health Center  
Marjory J. Johnson Chair of Hematology  
Translational Research  
Cincinnati Children's  
Professor, UC Department of Pediatrics

**Julie Kanter Washko, MD**

Associate Professor  
Division of Hematology Oncology  
University of Alabama at Birmingham  
1720 2nd Avenue South, NP 2540  
Birmingham, AL 35294-3300

**Kim Smith-Whitley, MD**

Professor of Pediatrics  
Director Comprehensive Sickle Cell Center  
Division of Hematology  
11th Floor Colket Building  
The Children's Hospital of Philadelphia  
34th & Civic Center Blvd.  
Philadelphia, PA 19104  
Board Member, Sickle Cell Disease  
Association of America

**Wanda Whitten-Shurney, MD**

CEO & Medical Director  
Sickle Cell Disease Association, Michigan  
Chapter Inc.  
Board Member, Sickle Cell Disease  
Association of America

**Ahmar U. Zaidi, MD**

**Assistant Professor of Pediatrics  
Comprehensive Sickle Cell Center  
Children's Hospital of Michigan  
Director of Physician Network  
Development, University Pediatricians  
Wayne State University/Central Michigan  
University School of Medicine  
Detroit, MI  
Ahmar@wayne.edu**